Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973280 | 1.00 | GLA (0.67) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1069692 | 1.00 | — | — | |
| SCHEMBL7027263 | 1.00 | GLA (0.67) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9352555 | 0.97 | — | — | |
| Ethylene Glycol SCHEMBL673538 | 0.92 | GLA (0.59) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| Propane SCHEMBL1995071 | 0.92 | GLA (0.59) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30918304 | 0.92 | GLA (0.59) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9058899 | 0.92 | CYP1A2 (0.61) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9131420 | 0.92 | CYP1A2 (0.61) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4350905 | 0.92 | CYP1A2 (0.61) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4694940-A1 | STEAP2-TARGETED COMPOUNDS AND USE THEREOF | Astrazeneca AB (SE) | 2026-02-18 | — | — | EP | claimed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-4634174-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | claimed |
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | claimed |
| US-20250288703-A1 | Alpha Emitter Compositions And Methods | NANT HOLDINGS IP LLC (US) | 2025-09-18 | — | — | US | claimed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| US-11433148-B2 | IGF-1R monoclonal antibodies and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-09-06 | — | — | US | claimed |
| US-20220054664-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-02-24 | — | — | US | claimed |
| US-20220040338-A1 | Alpha Emitter Compositions And Methods | NANT HOLDINGS IP, LLC | 2022-02-10 | — | — | US | claimed |
| CN-111263747-A | Bifunctional chelate pharmacokinetics enhancement and uses thereof | 融合制药公司 | 2020-06-09 | — | — | CN | claimed |
| WO-2020081174-A1 | ALPHA EMITTER COMPOSITIONS AND METHODS | NANT HOLDINGS IP, LLC (US) | 2020-04-23 | — | — | WO | claimed |
| EP-3638320-A2 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2020-04-22 | — | — | EP | claimed |
| CN-110891614-A | IGF-1R monoclonal antibody and application thereof | 融合制药公司 | 2020-03-17 | — | — | CN | claimed |
| US-20190083662-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | OXFORD FINANCE LLC | 2019-03-21 | — | — | US | claimed |
| US-20190030194-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2019-01-31 | — | — | US | claimed |
| WO-2018204872-A2 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2018-11-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288703-A1 | Alpha Emitter Compositions And Methods | PSMA2, TPSG1, FAP | GLA 39/4885CYP1A2 3766/4885MAPK1 4748/4885 |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | GLA 764/4885CYP1A2 4536/4885MAPK1 920/4885 |
| US-20190030194-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | SLC7A1, SLC19A1, PAICS | GLA 3397/4885CYP1A2 400/4885MAPK1 4881/4885 |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | GLA 1982/4885CYP1A2 4874/4885MAPK1 2991/4885 |
| US-20220054664-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | SLC7A1, SLC19A1, PAICS | GLA 3397/4885CYP1A2 400/4885MAPK1 4881/4885 |
| US-20190083662-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | IGF1R, IGFBP1, IGFBP2 | GLA 1177/4885CYP1A2 4831/4885MAPK1 2492/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | GLA 2602/4885CYP1A2 4412/4885MAPK1 1890/4885 |
| US-11433148-B2 | IGF-1R monoclonal antibodies and uses thereof | IGF1R, IGFBP1, IGFBP2 | GLA 1177/4885CYP1A2 4831/4885MAPK1 2492/4885 |
| US-20220040338-A1 | Alpha Emitter Compositions And Methods | PSMA2, TPSG1, FAP | GLA 39/4885CYP1A2 3766/4885MAPK1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.